{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:10:16Z","timestamp":1758892216080,"version":"3.44.0"},"reference-count":5,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>5-nitroimidazoles (5-NI) are pharmacologically diverse drugs used mainly for anaerobic and parasitic infections. Metronidazole is the most widely used 5-NI and has rare neurotoxic effects, including cerebellar and brainstem dysfunction, encephalopathy, and seizures. Other (5-NI) have been studied as hypoxic cell radiosensitizers but are limited by dose-dependent side effects. Nimorazole is in use in Denmark for head-and-neck cancer and is considered safe. No cases of nimorazole-induced neurotoxicity like Metronidazole encephalopathy have been published. In this case, we report a patient who developed toxic encephaloneuropathy during nimorazole radiosensitisation.<\/jats:p>","DOI":"10.61409\/v12240878","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T10:39:17Z","timestamp":1753958357000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["A case of toxic encephaloneuropathy during treatment with nimorazole"],"prefix":"10.61409","author":[{"given":"Shanga Hassan","family":"Qadir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Jakubauskaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie Lund","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998;46(2):135-146. https:\/\/doi.org\/10.1016\/S0167-8140(97)00220-X","DOI":"10.1016\/S0167-8140(97)00220-X"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"S\u00f8rensen CG, Karlsson WK, Amin FM, Lindelof M. Metronidazole-induced encephalopathy: a systematic review. J Neurol. 2020;267(1):1-13. https:\/\/doi.org\/10.1007\/s00415-018-9147-6","DOI":"10.1007\/s00415-018-9147-6"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858-883. https:\/\/doi.org\/10.1128\/CMR.00007-10","DOI":"10.1128\/CMR.00007-10"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Metwally MAH, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014;53(5):654-661. https:\/\/doi.org\/10.3109\/0284186X.2013.864050","DOI":"10.3109\/0284186X.2013.864050"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Thomson DJ, Slevin NJ, Baines H, et al. Randomized phase 3 trial of the hypoxia modifier nimorazole added to radiation therapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD). Int J Radiat Oncol Biol Phys. 2024;119(3):771-782. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.11.055","DOI":"10.1016\/j.ijrobp.2023.11.055"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:39:43Z","timestamp":1758890383000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V12240878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":5,"URL":"https:\/\/doi.org\/10.61409\/v12240878","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}